India Cefixime Market to grow at a steady rate During the Forecast Period
Increase in bacterial
infections is expected to drive the growth of India Cefixime market during the
forecast period.
According
to TechSci Research report, “India Cefixime Market By Route of
Administration (Oral v/s Intravenous), By Dose (100 mg, 200 mg, 500 mg, Others),
By Source (In-house v/s Contract Manufacturing Organizations), By Form (Tablet,
Capsule, Powder, Injection, Others), By Distribution Channel (Online v/s
Offline), By Application (Urinary tract infections, Otitis media, Pharyngitis
and tonsillitis, Others), By End User (Adult v/s Children), By Company, By
Region, Forecast & Opportunities, FY2026”, the India cefixime market is expected to grow at a steady
rate during the forecast period. Cefixime, is a third-generation cephalosporin
antibiotic. Cefixime is highly stable in the presence of beta-lactamase enzymes.
Cefixime is used to treat pharyngitis and tonsillitis caused by S. pyogenes. This in turn is expected to fuel the market
growth through FY2026. In addition to this, uncomplicated gonorrhea
(cervical/urethral) caused by Neisseria gonorrhoeae is also treated effectively
with the use of this drug API. However, side-effects associated with drug
consumption such as stomach upset/pain, diarrhea, nausea, gas, headache, or
dizziness can restrict the market growth over the next few years.
Browse XX market data Tables
and XX Figures spread through XXX
Pages and an in-depth TOC on " India Cefixime Market"
https://www.techsciresearch.com/report/india-cefixime-market/7195.html
The India Cefixime market is segmented based on route of administration,
dose, source, form, distribution channel, application, end user, company, and
region. Based on application, the market can be fragmented into urinary tract
infections, otitis media, pharyngitis and tonsillitis, others. The urinary
tract infections segment is expected to dominate the market in the forthcoming
years on account of rising cases of urinary tract infections caused by
susceptible isolates of Escherichia coli and Proteus mirabilis. Based on source,
the market can be categorized into in-house v/s contract manufacturing
organizations. The in-house segment dominated the market until 2019 because in-house
manufacturing helps in maintaining the quality and efficacy of the finished
product as the drug is manufactured in the company’s own R&D set up.
Contract manufacturing organizations segment is expected to witness significant
growth in the market on account of high scalability of products coupled with
substantial growth in number of contract manufacturers in the country. In terms
of distribution channel, the market is split into online and offline. The
offline channel is expected to dominate the market over the coming years as it
is more suitable for the consumers to buy medicines from a pharmacy in the
vicinity.
Covalent Laboratories Pvt. Ltd, Reva
Pharma Pvt. Ltd., Orchid Pharma Ltd., Unimark Remedies Ltd., Virchow Healthcare
Pvt. Ltd., Alkem Laboratories Limited, Aurobindo Pharma Limited, Taj Pharmaceuticals Ltd., Lupin
Pharmaceuticals Pvt. Ltd., Dr. Reddy’s Laboratories Ltd. and
others are some of the leading players operating in India cefixime market.
Companies operating in the market are using strategies such as product launches,
mergers, and collaborations, customer focused approach to boost their share and
increase their geographic reach.
Download Sample Report @ https://www.techsciresearch.com/sample-report.aspx?cid=7195
Customers can also request for
10% free customization on this report.
“India cefixime market is expected to
witness growth during the forecast period as it is used to treat uncomplicated
urinary tract infections. Also, Cefixime is defined as a broad spectrum
cephalosporin antibiotic which is used for treating bacterial infections of the
ear. This is further expected to create lucrative opportunities for the market
growth of India Cefixime market over the next five years.” said
Mr. Karan Chechi, Research Director with TechSci Research, a research based India
management consulting firm.
“India Cefixime Market By Route of Administration
(Oral v/s Intravenous), By Dose (100 mg, 200 mg, 500 mg, Others), By Source
(In-house v/s Contract Manufacturing Organizations), By Form (Tablet, Capsule,
Powder, Injection, Others), By Distribution Channel (Online v/s Offline), By Application
(Urinary tract infections, Otitis media, Pharyngitis and tonsillitis, Others), By
End User (Adult v/s Children), By Company, By Region, Forecast &
Opportunities, FY2026”, has
evaluated the future growth potential of India cefixime market and provides
statistics & information on market size, structure and future market
growth. The report intends to provide cutting-edge market intelligence and help
decision makers take sound investment decisions. Besides, the report also
identifies and analyzes the emerging trends along with essential drivers,
challenges and opportunities in India cefixime market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: [email protected]